AUTHORS
Nicha Wareesawetsuwan, MD, Betul Ibis, MD2, Anthos Christofides, MD PhD3, Konstantinos Aliazis, PhD4, Rushil Shah, BSc5, Rinku Pal, BS6, Monisha Kashyap, MD7, Vassiliki Boussiotis, MD PhD8
AFFILIATIONS
1 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, University of Minnesota-Twin Cities, Minneapolis, Minnesota, United States
2 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, Mt. Auburn Hospital, Boston, Massachusetts, United States
3 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
5 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, Ohio State University Medical College, Columbus, Ohio, United States
6 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
7 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
8 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Peroxisome proliferator-activated receptor β/δ (Pparβ/δ) is a fatty acid-activated nuclear transcription factor that regulates metabolic programs and has emerging roles in immune cell fate and function. Pparβ/δ is ubiquitously expressed and has been implicated in T cell development and function, although prior studies have reported divergent effects. While Pparβ/δ may support TCRβ-selected thymocyte proliferation and peripheral CD4+ T cell expansion, overexpression of Pparβ/δ can suppress DN4 thymocyte proliferation by shifting metabolism toward fatty acid oxidation. In autoimmune models, Pparβ/δ deficiency enhances Th1 and Th17 polarization while reducing Th2 and Treg differentiation, suggesting that Pparβ/δ regulates metabolism-dependent T cell differentiation fate. However, the T cell intrinsic role of Pparβ/δ in antigen (Ag)-driven and tumor-associated T cell responses remains poorly understood. In this study, we aimed to investigate how T cell-specific deletion of Pparβ/δ affects T cell composition, Ag-driven activation in vitro, and antitumor T cell responses in vivo. To achieve these goals, we crossed Pparβ/δfl/fl mice with CD4Cre mice, which express Cre under the control of the CD4 promoter and induce floxed gene deletion in all T cell subsets during thymic differentiation. Using this approach, we generated Pparβ/δfl/flCD4Cre mice with conditional Pparβ/δ deletion in T cells and compared the in vitro and in vivo functions of their T cells with those from Pparβ/δfl/fl control mice. At baseline, Pparβ/δfl/flCD4Cre mice showed reduced CD4+ and increased CD8+ T cell fractions in the spleen and lymph nodes. This skewing persisted after anti-CD3/CD28 stimulation in vitro suggesting that Pparβ/δ ablation predominantly compromised expansion of CD4+ T cells. To investigate Ag-specific CD4+ T cell activation, we generated Pparβ/δfl/flCD4Cre/OT-II mice expressing an OT-II transgenic T cell receptor, which is expressed in CD4+ T cells and recognizes the ovalbumin-derived peptide OVA323-339 presented by MHC class II. At baseline, Pparβ/δfl/flCD4Cre/OT-II mice showed reduced CD4+ T cell frequency, and increased CD8+ T cell and Foxp3+ Treg cell frequency in the spleen and lymph nodes. These changes were accompanied by reduced CD4+ and CD8+ effector memory T cells. After 72 hours of in vitro Ag-specific stimulation with OVA323-339 peptide or polyclonal stimulation with anti-CD3/CD28, the CD4/CD8 skewing persisted across conditions. Moreover, Pparβ/δ-deficient T cells showed greater impairment in OVA-driven responses than in anti-CD3/CD28 driven responses supporting a key role of Pparβ/δ during antigen-specific stimulation of CD4+ T cells. Consistent with this, following OVA stimulation, Pparβ/δ-deficient CD4+ T cells demonstrated attenuated induction of CD25, CD44, and CD69, together with impaired CD4+ effector cell differentiation confirming that Pparβ/δ deletion preferentially impairs Ag-specific CD4+ T cell activation. In line with these findings, thymidine incorporation at 72 hours in total splenocyte cultures was more prominently reduced after OVA-mediated stimulation than anti-CD3/CD28 mediated stimulation. To characterize the role of T cell-intrinsic Pparβ/δ in antitumor immunity in vivo, we compared Pparβ/δfl/flCD4Cre mice with Pparβ/δfl/fl controls in three different murine tumor models, the MC38 colon adenocarcinoma, MC17-51 fibrosarcoma, and B16-OVA melanoma. Pparβ/δ deletion significantly impaired tumor control in MC38 and MC17-51 tumors, as reflected by increased tumor volume and weight. A similar trend was observed in the B16-OVA tumor model, although the results did not reach statistical significance. Collectively, these results support a role for T cell-intrinsic Pparβ/δ in antitumor immunity, with its impact being more evident in the CD4+ T cell compartment. In conclusion, Pparβ/δ is an important regulator of Ag-driven CD4+ T cell activation, expansion, and effector differentiation. These findings suggest that therapeutic modulation of Pparβ/δ may be clinically relevant for optimizing antitumor T cell immunity.
DISCLOSURES
Nicha Wareesawetsuwan, MD: No relevant conflicts of interest to declare.